Although SEPT9 and PTGER4/SHOX2 methylation-based non- or minimally invasive tests are already commercially available for CRC and LC detection, respectively [19,20], they have limited sensitivity. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.